To examine the effects of pioglitazone, a PPARγ agonist, on memory performance and brain amyloidogenesis in streptozotocin (STZ)-induced diabetic mice. ICR male mice (aged 8–10 weeks old, weighing ...
New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS(R) ...
The FDA has released an updated safety announcement following a fresh review of data on the type 2 diabetes treatment pioglitazon to confirm that the drug may increase a person’s likelihood of ...
The thiazolidinedione pioglitazone improves advanced fibrosis as well as fibrosis of any stage in nonalcoholic steatohepatitis (NASH), even in patients without diabetes, a meta-analysis suggests. A ...
PRINCETON, N.J., Aug. 17, 2012 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), has launched authorized generic pioglitazone hydrochloride ...
Pioglitazone (as HCl) 30 mg, glimepiride 2 mg; tabs. Adjunct to diet and exercise in type 2 diabetes in patients already on pioglitazone + a sulfonylurea, or in patients on either pioglitazone or a ...
Actos (pioglitazone) is a prescription drug that’s used to treat type 2 diabetes. This drug can interact with other medications and some supplements. For example, Actos can interact with certain other ...
FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes First and only oral antidiabetic fixed-dose combination medication ...
Use of pioglitazone for 1 year or less, 1–2 years, and more than 2 years was associated with a 33%, 66%, and 78% increased risk of bladder cancer, respectively. A cumulative dose of 10,500 mg or less, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results